{"organizations": [], "uuid": "d2a6b2261bb165ab8734e1ccd0c7903f9db8c9f7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/08/21/vti-study-idUSL3N10W5A520150821", "country": "US", "title": "Vital Therapy drops studies after liver therapy fails trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "Vital Therapy drops studies after liver therapy fails trial | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-08-22T00:32:00.000+03:00", "replies_count": 0, "uuid": "d2a6b2261bb165ab8734e1ccd0c7903f9db8c9f7"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/08/21/vti-study-idUSL3N10W5A520150821", "ord_in_thread": 0, "title": "Vital Therapy drops studies after liver therapy fails trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Aug 21 Vital Therapies Inc said it would stop two studies of its liver therapy after the experimental treatment failed to meet its main goal in a late-stage study.\nThe company said it would drop the VTI-210 and VTI-212 studies, which were currently enrolling patients, and analyze data from its failed VTI-208 study.\nThe liver therapy was tested for its efficacy to improve overall survival in patients with alcohol-induced liver failure. (Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)", "external_links": [], "published": "2015-08-22T00:32:00.000+03:00", "crawled": "2015-08-21T23:42:40.240+03:00", "highlightTitle": ""}